Summit Therapeutics COO and CFO Manmeet Singh Soni purchased $361,500 worth of stock at $14.46 per share, marking the largest insider purchase in the company's history. This significant buy by C-suite leadership suggests confidence in the recent positive Phase III data for ivonescimab.
Price context
The stock is currently trading 16.56% above its 52-week low of $13.83, though it remains down 17.59% from its 52-week high of $30.98.
Catalysts to watch
- •Largest insider purchase in company history
- •Positive Phase III overall survival data for ivonescimab announced on June 4
- •Zacks rating upgrade to Buy on June 4
Risks
- •Short interest of 22.11% of the float remains elevated
- •Bernstein maintained an Underperform rating on June 2 citing concerns about the HARMONi-3 trial
AI-generated context from public data. Not investment advice. Verify before trading.